ClinicalTrials.gg
Active, not recruitingNCT04319783DECREASEUpdated Aug 21, 2025

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

A Phase 2 interventional study of Darolutamide and Radiotherapy in Advanced Prostate Carcinoma, Cancer of Prostate and PSA, sponsored by Trans Tasman Radiation Oncology Group. Active, not recruiting at 16 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Trans Tasman Radiation Oncology Group · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing darolutamide in Prostatic Neoplasms — 29 open to participants now, 40 under way, 10 of them phase 3. darolutamide · Prostatic Neoplasms.

Enrollment
35th of 59
65 · median 80
Started
2021
with 8 others
Phase 2
29 of 59
16 open now
Primary completion
2026-06
later than 9 of 39 live
Registered
18th of 59
by date

Among the 59 studies testing darolutamide in Prostatic Neoplasms, this one is the 35th largest by enrollment, is one of 9 that started in 2021, is one of 29 in phase 2, reaches primary completion later than 9 of the 39 other live ones, and was the 18th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

29 of the 59 studies testing darolutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About darolutamide

darolutamide: first FDA approval 2019 (NUBEQA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing darolutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that >90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.

Read the detailed description

This study explores the use of local consolidation therapy in the setting of Darolutamide in the initial diagnosis of metastatic castrate resistant prostate cancer (mCRPC). In the chemotherapy naïve mCRPC setting, the pattern of disease is of limited volume metastases (1-5) in 34%-40% of cases. As progression at known sites of macroscopic disease is the predominant cause of failure on systemic therapies, local consolidation therapy with stereotactic ablative body radiotherapy (SABR) may improve progression free survival (PFS) and overall survival (OS). This approach has been tested in the setting of lung cancer, in which consolidation SABR has resulted in OS benefit (HR of 0.40) in phase II studies. The novel approach of local consolidation therapy has not been tested as yet in mCRPC.

The secondary objective of this study proposal is to better understand the pattern of disease distribution at first diagnosis of CRPC. Previous studies have used conventional bone scan and CT imaging, and with these investigations the proportion of patients that are 'M0' is \~35%1. However, in the new era of PSMA PET, which is far more sensitive than conventional imaging, there exists a new group of men who are M0 on conventional imaging but are M1 on PSMA PET staging.

Thus, in the DECREASE study population, we expect the vast majority of patients with conventionally imaged 'M0 CRPC' will have disease detectable on PSMA PET scanning. In this context, the central hypothesis of this trial is that the addition of consolidation radiotherapy to darolutamide to PSMA detected sites of disease will improve the clinical outcome of patients compared to those patients receiving darolutamide alone.

03

Conditions studied

  • Advanced Prostate Carcinoma
  • Cancer of Prostate
  • PSA
  • Castrate Resistant Prostate Cancer

Browse trials for

Keywords

  • Darolutamide
  • Consolidation Radiotherapy
  • PSA
  • PSMA PET
  • Prostate Cancer
  • Advanced Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years of age and provided written
  • or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  • Castration-resistant prostate cancer, defined as at least 2 consecutive PSA rises obtained at least 1 week apart in the setting of castrate testosterone levels
  • Castrate level of serum testosterone (\<1.7 nmol/l [50 ng/dl]) on gonadotrophin - releasing hormone (GnRH) agonist or antagonist therapy or after bilateral orchiectomy
  • A baseline PSA level of at least 1ng per millilitre and a PSA doubling time of 10 months or less
  • Adequate bone marrow reserve and organ function (ECOG) performance status of 0 or 1
  • At least 1 site of PSMA-avid disease on PSMA-PET/CT imaging in any of the following regions; At least 1 site of PSMA-avid disease on PSMA-PET/CT imaging in any of the following regions:

    • Local recurrence within the prostate gland or prostate bed
    • Regional lymph node disease (below the aortic bifurcation)
    • Extra-pelvic lymph node, bone or soft tissue disease

Exclusion criteria

Exclusion Criteria:

  • Patients with detectable or a history of metastatic disease on conventional imaging
  • Prior treatment with second-generation androgen receptor (AR) antagonists, CYP17 enzyme inhibitors or oral ketoconazole
  • Use of oestrogens or 5-α reductase inhibitors or anti-androgens within 28 days before randomisation
  • Use of systemic with a dose greater than the equivalent 10 mg of prednisone/day within 28 days before randomisation
  • Radiotherapy within 12 weeks prior to randomisation
  • Initiation of treatment with an osteoclast-targeted therapy to prevent skeletal-related events within 12 weeks before randomisation
  • Any of the following within 6 months before randomisation: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure (NYHA) Class III or IV
  • Uncontrolled hypertension
  • Prior
  • Gastrointestinal disorder or procedure that expects to interfere significantly with the absorption of study treatment
  • Unable to swallow study medications and comply with study requirements
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Darolutamide

    Darolutimide 600mg BD

    Drug: Darolutamide

  • Experimental
    Local consolidation Radiotherapy + Darolutamide

    Darolutimide 600mg BD + local consolidative radiotherapy, with a biological equivalent dose of 30Gy/10fx or greater if delivered with SABR. SABR is the preferred treatment approach, however conventional radiotherapy is acceptable. To up to 5 sites of disease

    Drug: Darolutamide · Radiation: Radiotherapy

Interventions

  • Darolutamide alone

    Also known as: NUBEQA, Bayer HealthCare Pharmaceuticals Inc.

  • RadiationRadiotherapy

    Darolutamide + Consolidation Radiotherapy

06

What researchers measure

Primary outcomes

  1. Undetectable PSA at 12 months

    Undetectable PSA at 12 months

    Time frame: 12 months

Secondary outcomes

  1. Radiological progression free survival

    Radiological progression free survival

    Time frame: 36 months

  2. Distribution of disease on baseline PSMA-PET/CT imaging

    Distribution of bone, nodal, visceral and recurrent primary disease on PSMA-PET/CT

    Time frame: 36 months

  3. Biochemical progression free survival

    Biochemical progression free survival

    Time frame: 36 months

  4. Treatment related adverse event

    Treatment related adverse events (CTCAE v 5.0)

    Time frame: 36 months

  5. Overall survival

    Overall survival

    Time frame: 36 months

  6. Patterns of disease on PSMA PET/CT after 12 weeks of commencing Darolutamide, and at time of disease progression

    PSMA avid disease at irradiated site / unirradiated site / bone / local / nodal / visceral

    Time frame: 3 months

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2026, 60 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 60 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2020
First posted
Mar 24, 2020
StartActual
Jun 2, 2021
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04319783
Lead sponsor
Trans Tasman Radiation Oncology Group
Collaborators
Bayer, Peter MacCallum Cancer Centre, Australia
Responsible party
Sponsor
First posted
Mar 24, 2020
Start date
Jun 2, 2021
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Aug 21, 2025

Study contacts

Shankar Siva
study chair · Peter MacCallum Cancer Centre, Australia
Arun Azad
study chair · Peter MacCallum Cancer Centre, Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Darolutamide

Start the discussion